Cemex S.A.B. de C.V. Sponsored ADR vs Smith & Nephew plc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.47 (market cap $13.79B), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and Smith & Nephew plc for 120 Days on average.
| CX | SNN | |
|---|---|---|
Market Cap | $13.79B | $11.10B |
Volume | 3,993,982 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $37.17 |
52-Week Low | $9.12 | $26.42 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $19.79B | $14.13B |
Dividend Yield | 1.3% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →